Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium Shryock JC; Belardinelli LBr J Pharmacol 2008[Mar]; 153 (6): 1128-32This commentary on the review by DA Saint in the current issue of the British Journal of Pharmacology focuses on the pathological role of late I(Na) in the heart, the evidence supporting inhibition of late I(Na) as a therapeutic target in ischaemic heart disease, and the therapeutic applications and challenges for development of new late I(Na) inhibitors. Recent reports from a large clinical outcome trial (MERLIN) of ranolazine, a drug known to inhibit late I(Na), indicated that it was safe and reduced recurrent ischaemia and arrhythmic activity. In combination with other results indicating that inhibition of late I(Na) reduces ischaemia, myocardial Ca(2+) overload, and electrical and mechanical dysfunction when late I(Na) is increased, the new clinical trial results suggest that reduction of cardiac late I(Na) is safe and therapeutically beneficial.|Acetanilides/pharmacology[MESH]|Animals[MESH]|Calcium/metabolism[MESH]|Controlled Clinical Trials as Topic[MESH]|Drug Delivery Systems[MESH]|Drug Design[MESH]|Electrophysiology[MESH]|Enzyme Inhibitors/pharmacology[MESH]|Humans[MESH]|Myocardial Ischemia/*drug therapy/physiopathology[MESH]|Piperazines/pharmacology[MESH]|Ranolazine[MESH]|Sodium Channel Blockers/*pharmacology[MESH]|Sodium Channels/*drug effects/metabolism[MESH] |
